(71 days)
Not Found
No
The description focuses on infrared spectroscopic analysis and calculating ratios, with no mention of AI or ML techniques.
No
This device is an in vitro diagnostic device used to detect H. pylori infection, not to treat it.
Yes
The "Intended Use / Indications for Use" section explicitly states, "The UBiT-IR300 Infrared Spectrometry System is an in vitro diagnostic device designed to measure changes in 13CO2 content in breath CO2 gas by infrared spectroscopic analysis."
No
The device description explicitly lists hardware components: the UBiT-IR300 Infrared Spectrophotometer, the UBiT-AS10 Autosampler, and Otsuka Breath Collection Bags.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the UBiT-IR300 Infrared Spectrometry System is an in vitro diagnostic device.
- Measurement of Biological Samples: The device is designed to measure changes in 13CO2 content in breath CO2 gas, which is a biological sample collected from a patient.
- Diagnostic Purpose: The system is intended for use in conjunction with 13C-urea breath tests for the detection of Helicobacter pylori (H. pylori) infection. Detecting an infection is a diagnostic purpose.
- Clinical Setting: The device is intended for use in clinical laboratory and point-of-care settings, which are typical environments for IVD use.
N/A
Intended Use / Indications for Use
The UBiT-IR300 Infrared Spectrometry System is an in vitro diagnostic device designed to measure changes in 13CO2 content in breath CO2 gas by infrared spectroscopic analysis. The system consists of the UBiT-IR300 Infrared Spectrophotometer, the UBiT-AS10 Autosampler, and Otsuka Breath Collection Bags.
The UBiT-IR300 Infrared Spectrometry System is intended for use in conjunction with commercially available Meretek 13C-urea breath tests for the detection of Helicobacter pylori (H. pylori) infection. The UBiT-IR300 System is suitable for use in both clinical laboratory and point-of-care settings.
Product codes (comma separated list FDA assigned to the subject device)
JJQ, MSQ
Device Description
The UBiT-IR300 Infrared Spectrometry System is a compact analyzer designed for use in conjunction with commercially available Meretek 13C-urea breath tests for the detection of Helicobacter pylori. The UBiT-IR300 measures absorption of breath gas by calculating the ratios of 13CO2/12CO2 for a reference breath gas and a sample breath gas. The difference between the ratios for the reference and sample breath gases is calculated to obtain the final measurement result, which is reported as △'3CO2 and expressed as delta per mil % or Delta Over Baseline (DOB).
The System consists of the following components:
- UBiT-IR300 Infrared Spectrophotometer
- UBiT-AS10 Autosampler
- Otsuka Breath Collection Bags
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
clinical laboratory and point-of-care settings.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A clinical study was conducted to evaluate the performance of the UBiT-IR300 Infrared Spectrometry System to measure changes in '3CO2 content in breath CO2 gas by infrared spectroscopic analysis. The multi-center, prospective study was designed to compare the UBiT-IR300 Infrared Spectrophotometer for measuring 13CO2 enrichment in breath with the traditional Gas Isotope Ratio Mass Spectrometry (GIRMS) method. Subjects were recruited from four Physician Office Laboratory (POL) settings and one clinical laboratory setting. Subjects underwent a standard urea breath test (UBT) which is used for the detection of Helicobacter pylori (H. pylori) infection. Analyses of breath samples were performed using both the UBiT-IR300 Infrared Spectrophotometer and GIRMS methods. The number of evaluable subjects was 257 for the combined POL sites and 63 for the clinical laboratory site with a total of 320 evaluable subjects across all participating sites.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Nonclinical Testing: The UBiT-IR300 and UBiT-AS10 were tested to and comply with IEC 60601-1 and IEC 60601-1-2. Reproducibility and carry-over studies were conducted on the UBiT-IR300 alone and with the UBiT-IR300 connected to the UBiT-AS10 Autosampler. These studies demonstrate that the UBiT-IR300 performs according to its specifications and there is negligible carryover.
Clinical Testing: A multi-center, prospective clinical study was conducted using 320 evaluable subjects (257 from POL sites and 63 from a clinical laboratory site). The primary endpoint was the percent agreement of the UBiT-IR300 results as compared to the result generated by the GIRMS method using a cut-off value of 2.4 Delta Over Baseline (DOB). Results for all POLs plus the clinical laboratory are as follows:
- % Overall Agreement: 99.06% [95% CI: (97.35, 99.74)]
- % Positive Agreement: 98.29% [95% CI: (94.26, 99.70)]
- % Negative Agreement: 99.51% [95% CI: (97.49, 99.97)]
As a secondary endpoint, paired Delta Over Baseline (DOB) values were analyzed directly to determine the extent to which the methods were linearly related and the degree to which they were correlated. Comparison of the paired DOB values demonstrates that the two methods give results which are very highly correlated (r>.99) and appear to be linearly related to one another. The data suggest that the regression lines pass through the origin with a slope very near one.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
% Overall Agreement: 99.06% [95% CI: (97.35, 99.74)]
% Positive Agreement: 98.29% [95% CI: (94.26, 99.70)]
% Negative Agreement: 99.51% [95% CI: (97.49, 99.97)]
Correlation Coefficient (r): >.99 (between paired DOB values of UBiT-IR300 and GIRMS)
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.2300 Colorimeter, photometer, or spectrophotometer for clinical use.
(a)
Identification. A colorimeter, a photometer, or a spectrophotometer for clinical use is an instrument intended to measure radiant energy emitted, transmitted, absorbed, or reflected under controlled conditions. The device may include a monochromator to produce light of a specific wavelength.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
0
510(k) Summary
K01337/
for UBiT-IR300 Infrared Spectrometry System
SPONSOR 1.
Otsuka Pharmaceutical Co., Ltd. 2-9, Kanda Tsukasa-cho, Chiyoda-ku Tokyo 101-8535 Japan
Contact Person: Hideji Nonomura Japan: 81-88-665-2126 Telephone:
Mr. Yasuo Irie U.S .: 978-749-8000 Telephone:
December 17, 2001 Date Prepared:
DEVICE NAME 2.
| Proprietary Name: | UBIT-IR300 Infrared Spectrometry System |
|---|---|
| Common/Usual Name: | Infrared Spectrometry System |
| Classification Name: | Colorimeter, Photometer, or Spectrophotometer for Clinical Use |
For use of the UBiT-IR300 System in conjunction with commercially available Meretek 13C-urea breath tests for the detection of Helicobacter pylori (H. pylori) infection, the following are also applicable:
Analysis System for Use with 13C-Urea Breath Test Common/Usual Name: Classification Name: Urea Breath Test
Predicate Devices 3.
- ABCA-NT Gas Isotope Ratio Mass Spectrometer (GIRMS) System . Europa Scientific Limited K974322
1
DEVICE DESCRIPTION 4.
The UBiT-IR300 Infrared Spectrometry System is a compact analyzer designed for use in conjunction with commercially available Meretek 13C-urea breath tests for the detection of Helicobacter pylori. The UBiT-IR300 measures absorption of breath gas by calculating the ratios of 13CO2/12CO2 for a reference breath gas and a sample breath gas. The difference between the ratios for the reference and sample breath gases is calculated to obtain the final measurement result, which is reported as △'3CO2 and expressed as delta per mil (%) or Delta Over Baseline (DOB).
The System consists of the following components:
- UBiT-IR300 Infrared Spectrophotometer -
- UBiT-AS10 Autosampler -
- Otsuka Breath Collection Bags -
INTENDED USE న్.
The UBiT-IR300 Infrared Spectrometry System is an in vitro diagnostic device designed to measure changes in 1302 content in breath CO2 gas by infrared spectroscopic analysis. The system consists of the UBiT-IR300 Infrared Spectrophotometer, the UBiT-AS10 Autosampler, and Otsuka Breath Collection Bags.
The UBiT-IR300 Infrared Spectrometry System is intended for use in conjunction with commercially available Meretek 13C-urea breath tests for the detection of Helicobacter pylori (H. pylori) infection. The UBiT-IR300 System is suitable for use in both clinical laboratory and point-of-care settings.
TECHNOLOGICAL CHARACTERISTICS AND SUBSTANTIAL EQUIVALENCE 6.
Both the UBiT-IR300 System and the ABCA-NT are general purpose instrument systems that are intended to measure changes in 13CO2 content in breath CO2 and have many potential applications. One of the applications for these systems is for use with commercially available 13C-urea breath tests (13C-UBT) for H. pylori. Meretek Urea Breath Test Collection Kits can be used in conjunction with either system and the required breath samples collected for analysis.
2
The UBiT-IR300 System includes specially designed breath collection bags that subjects blow into for collection of the breath samples. The ABCA-NT uses standard commercially available evacuated tubes for collection of breath samples.
The UBiT-IR300 and the ABCA-NT systems are similar in functional design but use different methods of gas measurement. The UBiT-IR300 uses an infrared spectrophotometer to analyze the gas samples, while the ABCA-NT uses a Gas Isotope Ratio Mass Spectrometer (GIRMS). The UBiT-IR300 is smaller and more compact than the ABCA-NT, and is specifically designed for on-site use. Both systems include an autosampler and a computer for data analysis and storage. The UBiT-IR300 computer is built into the analyzer, while the ABCA-NT has an external computer system.
PERFORMANCE TESTING 7.
Nonclinical Testing 7.1
The UBiT-IR300 and UBiT-AS10 were tested to and comply with IEC 60601-1 and IEC 60601-1-2.
Reproducibility and carry-over studies were conducted on the UBiT-IR300 alone and with the UBiT-IR300 connected to the UBiT-AS10 Autosampler. These studies demonstrate that the UBiT-IR300 performs according to its specifications and there is negligible carryover.
7.2 Clinical Testing
A clinical study was conducted to evaluate the performance of the UBiT-IR300 Infrared Spectrometry System to measure changes in '3CO2 content in breath CO2 gas by infrared spectroscopic analysis. The multi-center, prospective study was designed to compare the UBiT-IR300 Infrared Spectrophotometer for measuring 13CO2 enrichment in breath with the traditional Gas Isotope Ratio Mass Spectrometry (GIRMS) method. Subjects were recruited from four Physician Office Laboratory (POL) settings and one clinical laboratory setting. Subjects underwent a standard urea breath test (UBT) which is used for the detection of Helicobacter pylori (H. pylori) infection. Analyses of breath samples were performed using both the UBiT-IR300 Infrared Spectrophotometer and GIRMS methods. The number of evaluable subjects was 257 for the combined POL sites and 63 for the clinical laboratory site with a total of 320 evaluable subjects across all participating sites.
3
The primary endpoint was the percent agreement of the UBiT-IR300 results as compared to the result generated by the GIRMS method using a cut-off value of 2.4 Delta Over Baseline (DOB). Results for all POLs plus the clinical laboratory are as follows:
| % Overall Agreement: | 99.06% [95% CI: (97.35, 99.74)] |
|---|---|
| % Positive Agreement: | 98.29% [95% CI: (94.26, 99.70)] |
| % Negative Agreement: | 99.51% [95% CI: (97.49, 99.97)] |
As a secondary endpoint, paired Delta Over Baseline (DOB) values were analyzed directly in order to determine the extent to which the methods were linearly related and the degree to which they were correlated. Comparison of the paired DOB values demonstrates that the two methods give results which are very highly correlated (r>.99) and appear to be linearly related to one another. The data suggest that the regression lines pass through the origin with a slope very near one.
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Otsuka Pharmaceutical Co., Limited c/o Ms. Cynthia A. Sinclair, RAC Senior Staff Consultant Medical Device Consultants, Inc. 49 Plain Street North Attleboro, MA 02760
Received: October 11, 2001
DEC 2 1 2001
Re: K013371
Trade/Device Name: UBiT-IR300 Infrared Spectrometry System Regulation Number: 21 CFR 862.2300, 866.3110 Regulation Name: Colorimeter, Photometer, Spectrophotometer for Clinical Use, Urea Breath Tests Regulatory Class: Class I Product Code: JJQ, MSQ Dated: October 9, 2001
Dear Ms. Sinclair:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
5
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed nouticate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (2) CFR Part 801 and 1 II you desire specific dayse for your astic devices), please contact the Office of Compliance at additionally 607.10 for in The carguestions on the promotion and advertising of your device, (301) 594-4566. Traditional (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small monthation on your responsiver Assistance at its toll-free number (800) 638-2041 or 1401) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________
Device Name: __ UBiT-IR300 Infrared Spectrometry System
Indications For Use:
The UBiT-IR300 Infrared Spectrometry System is an in vitro diagnostic device The UDIT 11000 mm changes in 18CO2 content in breath CO2 gas by infrared The system consists of the UBiT-IR300 Infrared spectroscopic analysis. Spections of the UBiT-AS10 Autosampler, and Otsuka Breath Collection Bags.
The UBiT-IR300 Infrared Spectrometry System is intended for use in conjunction with The OB1 - 11000 and Meretek 13C-urea breath tests for the detection of Helicobacter evlari (H. pylori) infection. The UBiT-IR300 System is suitable for use in both clinical laboratory and point-of-care settings.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NECESSARY)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Luddi lu. Poole
boratory Devices
510(k) Number K013371
Prescription Use
(Per 21 CFR 801.109)
OR
Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________
(Optional Format 1-2-96)